key: cord-1042330-sn9vibum authors: Bartelt, Luther; van Duin, David title: An Overview of COVID-19 in solid organ transplantation date: 2022-02-18 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2022.02.005 sha: 7053a7823f251537de3566ae74ab49650b95ad47 doc_id: 1042330 cord_uid: sn9vibum BACKGROUND: The COVID-19 pandemic has influenced the field of solid organ transplantation (SOT) in many ways. COVID-19 has led to programmatic impacts and changes in donor and recipient selection. Several studies have evaluated the course, optimal treatment, and prevention of COVID-19 in SOT recipients. OBJECTIVE: To review the literature on COVID-19 in SOT recipients. SOURCES: PubMed, Web of Science, and Google Scholar were searched. The search was restricted to articles published between January 1, 2019, and December 1, 2021. CONTENT: The COVID-19 pandemic initially led to a decreased volume of solid organ transplants. However, transplant volumes at most centers have rebounded. Donor selection remains an incompletely defined issue. Several reports suggests that donor-derived SARS-CoV-2 infections occur only in lung transplant recipients, and that other organs from SARS-CoV-2 PCR-positive donors could potentially be safely used. However, these data are limited to case series. Transplantation for end-stage lung disease after COVID-19 infection is increasingly common and has been performed with acceptable outcomes. In acute COVID-19 in a transplant candidate, transplantation should be delayed when feasible. After adjustment, mortality after COVID-19 appear similar in SOT recipients as compared to the general population, with notable increased use of anti-viral and anti-inflammatory treatment options. Prevention of COVID-19 is key in SOT recipients. Vaccination of SOT recipients and anyone who is in contact with SOT recipients is one of the cornerstones of prevention. Non-pharmacological interventions such as face coverings, hand hygiene, and physical distancing remain ever important as well. IMPLICATIONS: The COVID-19 pandemic continues to have an important impact on SOT candidates and recipients. Prevention of infection is the most important measure, and requires careful attention to approaches to vaccination, and messaging of the ongoing need for face coverings, physical distancing, and hand hygiene. with active COVID-19 was successfully used [17] . In another reported case, a living liver 127 donor developed COVID-19 symptoms 3 days after donation, but the unvaccinated 128 recipient did not develop symptoms, and tested negative on post-operative days 4 and 5 129 [18]. Taken together, these reports of successful transplantation of non-respiratory 130 organs from actively infected donors suggest that non-respiratory organ transplantation 131 all potential donors, regardless of COVID-19 symptoms [19] . NAT is preferred to rapid 138 antigen testing given the greater sensitivity for detecting SARS-CoV-2 RNA. However, 139 NAT turnaround times can vary greatly between laboratories and regions and the 140 resulting time-lag between testing and organ procurement could potentially result in a 141 misclassified donor converting to NAT positive by the time of organ procurement [20] . 142 Most centers therefore require NAT within 72 hours of organ procurement. Combined, these case reports support lung transplantation as a treatment option for a PCR-positive patient Lung transplantation 446 during the outbreak of Coronavirus Disease 2019 in China Lung transplantation as 449 therapeutic option in acute respiratory distress syndrome for coronavirus disease 450 2019-related pulmonary fibrosis First 452 lung transplantation as a treatment of a patient supported with extracorporeal 453 membrane oxygenation (ECMO) after COVID-19 in Poland COVID-19 in solid organ transplant recipients: A national cohort study from Sex and 472 organ-specific risk of major adverse renal or cardiac events in solid organ 473 transplant recipients with COVID-19 Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort 476 COVID-19 infection more severe in kidney transplant recipients? Clinical characteristics and outcomes of COVID-19 in solid organ transplant 491 recipients: A cohort study A 493 propensity score-matched analysis of mortality in solid organ transplant patients 494 with COVID-19 compared to non-solid organ transplant patients Outcomes of critically ill solid organ transplant patients with COVID-19 in the 498 United States Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort 501 study COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A 507 comparative analysis from a multicenter study Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and 514 Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case 515 -depth virological assessment of kidney transplant recipients with COVID-518 Long-term 520 shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19 tool for early prediction of COVID-19-associated death in kidney transplant 531 recipients of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis Impact 537 of immunosuppressive therapy on the severity of COVID-19 in solid organ 538 transplant recipients Inpatient COVID-19 outcomes in solid organ transplant recipients compared to 541 non-solid organ transplant patients: A retrospective cohort SARS-CoV-2 and Health Care Worker Protection in Settings: a Review of Modes of Transmission and a Novel Airborne Model Involving Inhalable Particles Adaptive 547 lymphocyte profile analysis discriminates mild and severe forms of after solid organ transplantation Neutralizing antibody levels are highly predictive of immune protection from 558 symptomatic SARS-CoV-2 infection SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in 561 heart and lung transplant recipients Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Three Doses of 570 an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients Solid Organ Transplant Recipients: A Case Series SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ 585 Transplant Recipients With Prior COVID-19 Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant 588 Recipients Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in 591 Recipients of a Solid Organ Transplant Clinical effectiveness of COVID-19 593 vaccination in solid organ transplant recipients. Transpl Infect Dis SARS-CoV-2 Vaccine in Kidney Transplant Recipients Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients